0000950103-23-016107.txt : 20231108 0000950103-23-016107.hdr.sgml : 20231108 20231108160634 ACCESSION NUMBER: 0000950103-23-016107 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Material Impairments ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acutus Medical, Inc. CENTRAL INDEX KEY: 0001522860 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 451306615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39430 FILM NUMBER: 231387819 BUSINESS ADDRESS: STREET 1: 2210 FARADAY AVE STREET 2: SUITE 100 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 442-232-6080 MAIL ADDRESS: STREET 1: 2210 FARADAY AVE STREET 2: SUITE 100 CITY: CARLSBAD STATE: CA ZIP: 92008 8-K 1 dp202619_8k.htm FORM 8-K
false 0001522860 0001522860 2023-11-06 2023-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549 

____________________________

 

FORM 8-K 

____________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): November 6, 2023

____________________________

 

 

Acutus Medical, Inc.

(Exact name of Registrant as Specified in Its Charter) 

____________________________

 

Delaware 001-39430 45-1306615

(State or Other Jurisdiction

of Incorporation)

 (Commission File Number)

(IRS Employer 

Identification No.)

 

2210 Faraday Ave., Suite 100

Carlsbad, CA

   92008
(Address of Principal Executive Offices)   (Zip Code)

 

 

Registrant’s Telephone Number, Including Area Code: (442) 232-6080

 

Not Applicable 

(Former Name or Former Address, if Changed Since Last Report)

____________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.001 AFIB

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

1 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 8, 2023, Acutus Medical, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 2.02 of this Current Report on Form 8-K.

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

 

On November 6, 2023, the Board approved a strategic realignment of resources and corporate restructuring (the “Restructuring”) designed to reallocate capital from its mapping and ablation businesses to its left-heart access distribution relationship with Medtronic, Inc. (“Medtronic”). The Company will wind down the mapping and ablation businesses and will no longer manufacture or distribute the AcQMap Mapping System, the AcQMap 3D Mapping Catheter, the AcQBlate Force-Sensing Ablation Catheter, the AcGuide Max 2.0 steerable sheath, and associated accessories, and will explore strategic alternatives for these businesses (including a potential sale of related assets). Following the Restructuring, the Company will focus exclusively on the manufacturing and distribution of left-heart access products to Medtronic to continue to generate revenue from such sales and potentially earn the associated earnout payments it may become eligible to receive under the Asset Purchase Agreement dated April 26, 2022, between the Company and Medtronic.

 

As part of the Restructuring, the Company announced a workforce reduction of approximately 160 employees, representing approximately 65% of the Company’s employees, that is expected to be completed by the first quarter of 2024. In compliance with the Worker Adjustment and Retraining Notification Act, the Company has provided pre-termination notices to affected employees and government authorities where required. The Company plans to enter into retention arrangements with certain employees who are expected to remain with the Company to assist with the Restructuring and operation of its left-heart access distribution business.

 

The Company estimates it will incur approximately $21 million to $32 million of pre-tax restructuring and exit-related charges, of which $2 million to $3 million represents future cash expenditures for the payment of severance and related benefit costs, $3 million to $4 million represents future cash expenditures for the payment of retention bonuses to certain employees that will assist with the Restructuring, $2 million to $5 million represents future cash expenditures for other restructuring costs, and approximately $14 million to $20 million represents non-cash pre-tax impairment charges in connection with the disposition of certain assets, including inventory, fixed assets and intangibles. The Company expects that a majority of the non-cash charges will be incurred in the fourth quarter of 2023, while the majority of the future cash charges will be incurred in the first quarter of 2024, and that the Restructuring will be substantially complete in the first quarter of 2024. 

 

Potential position eliminations in each country are subject to local law and consultation requirements, which may extend the Restructuring implementation beyond the first quarter of 2024 in certain countries. The charges that the Company expects to incur are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual expenses may differ from the estimates disclosed above. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring. 

 

2 

 

Item 2.06 Material Impairments.

 

The information set forth under Item 2.05 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Planned Departure of President and Chief Executive Officer; Chief Administrative Officer, General Counsel and Secretary; and Senior Vice President, Commercial

 

As part of the reduction in workforce described above, (i) David Roman, the Company’s President and Chief Executive Officer, and Kevin Mathews, the Company’s Senior Vice President, Commercial, are expected to separate from the Company, effective January 7, 2024 and (ii) Tom Sohn, the Company’s Chief Administrative Officer, General Counsel and Secretary, is expected to separate from the Company, effective February 6, 2024. The separations of Mr. Roman, Mr. Mathews, and Mr. Sohn are not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. This event meets the definition of a Qualifying Termination pursuant to the employment agreements of each of Mr. Roman, Mr. Mathews and Mr. Sohn entered into with the Company effective March 2021 (amended July 2022), May 2022, and August 2020, respectively. As a result, each of Mr. Roman, Mr. Mathews, and Mr. Sohn are eligible to receive certain payments and benefits following their separation in accordance with such agreements, each as described in the Company’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2023 (the “Proxy Statement”) or included with the Company’s Form 10-Q filed with the SEC on May 11, 2023. 

 

In connection with their departures, on November 6, 2023, the Board approved the acceleration of vesting of certain restricted stock units of the Company (“RSUs”) granted to (i) certain terminated employees, in connection with the reduction in workforce and (ii) each of Mr. Roman, Mr. Mathews, and Mr. Sohn, on March 1, 2023 under the Company’s 2020 Equity Incentive Plan, representing 67,500 RSUs, 21,250 RSUs and 21,250 RSUs, respectively, for the officers, which were originally scheduled to vest on March 1, 2024 pursuant to the terms of such grants. Such RSUs will now fully vest on each such officer’s scheduled last day of employment with the Company on either January 7, 2024, or February 6, 2024, as applicable, subject to their continued employment with the Company through such date.

 

In addition, on November 6, 2023, the Board approved a one-time retention bonus of $300,000 for Mr. Roman, $38,000 for Mr. Mathews, and $188,000 for Mr. Sohn, provided that each such officer remains employed by the Company on January 7, 2024 or February 6, 2024, as applicable.

 

Appointment of Takeo Mukai as Chief Executive Officer

 

On November 6, 2023, the Board approved the appointment of Takeo Mukai as the Company’s Chief Executive Officer, effective January 8, 2024, subject to the completion of the Restructuring, including the transition of executive management as described above. Mr. Mukai will also retain his position as the Company’s Chief Financial Officer.

 

Mr. Mukai has served as the Company’s Chief Financial Officer since January 2023. Mr. Mukai’s biographical information is described in the Proxy Statement. There are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Mukai and any of the Company’s executive officers or directors or persons nominated or chosen to become directors or executive officers. There is no arrangement or understanding between Mr. Mukai and any other person pursuant to which Mr. Mukai was appointed as Chief Executive Officer or a member of the Board. There are no transactions requiring disclosure under Item 404(a) of Regulation S-K.

 

In connection with Mr. Mukai’s appointment as the Company’s Chief Executive Officer, effective January 8, 2024, subject to the completion of the Restructuring, the Board approved a one-time retention bonus of $231,000 for Mr. Mukai.

 

Termination of Employee Stock Purchase Plan

 

3 

 

On November 6, 2023, the Board terminated the 2020 Employee Stock Purchase Plan (“2020 ESPP”), effective November 8, 2023, and resolved to return to the respective contributors all contributions made during the purchase period ending November 14, 2023. No new purchase periods under the 2020 ESPP will commence as of the date of termination.

 

Item 7.01 Regulation FD Disclosure.

 

On November 8, 2023, the Company issued a press release announcing the Restructuring. A copy of the press release is furnished as Exhibit 99.2 hereto and incorporated by reference herein.

 

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 7.01 of this Current Report on Form 8-K.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K and certain information incorporated herein by reference contain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Current Report on Form 8-K, other than statements that are purely historical, are forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may” and similar expressions also identify forward-looking statements. The forward-looking statements include, without limitation, statements regarding the Restructuring, including the estimated timing and cost savings; whether the Restructuring will be successfully completed; the benefits of the Restructuring; the anticipated timing and details of the reduction in workforce; the expected charges and costs associated with the Restructuring; the Company’s plans to retain certain individuals as employees or consultants to assist in the Restructuring; the potential for and timing of the consummation of sales of the Company’s assets or other strategic alternatives; and the Company’s business plans and objectives.

 

Our expectations, beliefs, objectives, intentions and strategies regarding future results are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from results contemplated by our forward-looking statements. Factors that may affect the actual results achieved by the Company include, without limitation, the risk that the Company may not be able to implement the Restructuring or the exploration of strategic alternatives as currently anticipated or within the timing currently anticipated; the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits; the impact of the workforce reduction on the Company’s remaining left-heart access distribution business; the possibility that executives or other employees may resign or be terminated; the Company’s ability to collaborate successfully with its strategic partners; the willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases; the risk that the Company’s remaining left-heart access distribution business does not advance or result in anticipated revenue; unexpected costs, charges or expenses that reduce the Company’s capital resources; the Company’s ability to continue to pay its obligations in the ordinary course of business as they come due; unanticipated difficulties in terminating certain contracts and arrangements; the Company’s ability to maintain its listing on Nasdaq; and the risk factors listed from time to time in the Company’s filings with the SEC, as further described below.

 

We urge you to carefully consider risks and uncertainties and review the additional disclosures we make concerning risks and uncertainties that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made under the captions “Risk Factors” contained in our most recently filed Form 10-K and Form 10-Q and subsequent filings with the SEC, as well as the press releases attached as Exhibits 99.1 and 99.2 hereto. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Current Report on Form 8-K.

 

4 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit

Number 

   Description
99.1*   Press Release dated November 8, 2023 regarding financial results for the quarter ended September 30, 2023
99.2*   Press Release dated November 8, 2023 announcing the Restructuring
104.0   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Furnished herewith, not filed. 

 

5 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Acutus Medical, Inc.
     
     
Date: November 8, 2023 By: /s/ Tom Sohn
    Tom Sohn
    Chief Administrative Officer, General Counsel and Secretary

6 

 EX-99.1 2 dp202619_ex9901.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

 

Acutus Medical Reports Third Quarter 2023 Financial Results

 

CARLSBAD, Calif., November 8, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023.

 

Recent Highlights:

 

•Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to Medtronic

 

•Registered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expense management

 

•Announced strategic realignment of resources and corporate restructuring with the objective of optimizing financial position and maximizing free cash flow

 

Third Quarter 2023 Financial Results
Revenue was $5.2 million for the third quarter of 2023, an increase of 44% compared to $3.6 million for the third quarter of 2022. The improvement over the same quarter last year was primarily driven by sales through the Company’s distribution agreement with Medtronic, higher capital sales, and increases in service, rent and other revenue.

 

Gross margin on a GAAP basis was negative 64% for the third quarter of 2023 compared to negative 91% for the same quarter last year. Non-GAAP gross margin was negative 60% for the third quarter of 2023 compared to negative 109% for the same quarter last year. The improvement on both a GAAP and non-GAAP basis was driven by higher production volumes primarily related to left-heart access manufacturing, lower manufacturing variances, and reduced manufacturing overhead expenses.

 

Operating expenses, consisting of research and development and selling, general and administrative expenses on a GAAP basis were $12.2 million for the third quarter of 2023 compared to $15.6 million for the same quarter last year. Non-GAAP operating expenses were $11.1 million for the third quarter of 2023 compared to $15.2 million for the same quarter last year. The decrease in operating expenses on both a GAAP and Non-GAAP basis resulted from reduced discretionary spend, and the reprioritization of certain research and development programs.

 

Net loss on a GAAP basis was $13.2 million for the third quarter of 2023 and net loss per share was $0.45 on a weighted average basic and diluted outstanding share count of 29.3 million, compared to a net loss of $20.4 million and a net loss per share of $0.72 on a weighted average basic and diluted outstanding share count of 28.4 million for the same quarter last year. Non-GAAP net loss for the third quarter of 2023 was $15.2 million, or $0.52 per share, compared to non-GAAP net loss of $20.0 million, or $0.70 per share, for the third quarter of 2022.

 

Cash, cash equivalents, marketable securities and restricted cash were $45.5 million as of September 30, 2023.

 

Outlook
Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

 

Non-GAAP Financial Measures
This press release includes references to non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss and non-GAAP basic and diluted net loss per share, which are non-GAAP financial measures, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important indicators of its operating performance because they exclude items that are primarily non-cash accounting line items unrelated to,

 

 

and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as Acutus calculates them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. Non-GAAP net loss is defined as net loss before income taxes, and all non-GAAP figures provided herein adjust for stock-based compensation, amortization of acquisition-related intangibles, employee retention credit, restructuring charges, changes in the fair value of contingent consideration, gain on sale of business, and change in fair value of warrant liability (as applicable). To the extent such non-GAAP financial measures are used in the future, the Company expects to calculate them using a consistent method from period to period. A reconciliation of the most directly comparable GAAP financial measure to the non-GAAP financial measure has been provided under the heading “Reconciliation of GAAP Results to Non-GAAP Results” in the financial statement tables attached to this press release.

 

About Acutus
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

 

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

 

 

ACUTUS MEDICAL, INC.

Condensed Consolidated Balance Sheets

(in thousands, except per share amounts)

 

   September 30, 2023  December 31, 2022
    (unaudited)      
ASSETS          
Current assets:          
Cash and cash equivalents  $24,100   $25,584 
Marketable securities, short-term   14,375    44,863 
Restricted cash, short-term   7,015    5,764 
Accounts receivable   8,952    21,085 
Inventory   15,728    13,327 
Employer retention credit receivable   —    4,703 
Prepaid expenses and other current assets   2,467    2,541 
Total current assets   72,637    117,867 
           
Property and equipment, net   6,611    9,221 
Right-of-use asset, net   3,359    3,872 
Intangible assets, net   1,433    1,583 
Other assets   688    897 
Total assets  $84,728   $133,440 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable  $4,754   $4,721 
Accrued liabilities   7,438    9,686 
Contingent consideration, short-term   —    1,800 
Operating lease liabilities, short-term   707    319 
Warrant liability   1,868    3,346 
Total current liabilities   14,767    19,872 
           
Operating lease liabilities, long-term   3,462    4,103 
Long-term debt   34,761    34,434 
Other long-term liabilities   32    12 
Total liabilities   53,022    58,421 
           
Commitments and contingencies          
           
Stockholders' equity          
Preferred stock, $0.001  par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of September 30, 2023 and December 31, 2022   —    — 
Common stock, $0.001 par value; 260,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 29,289,934 and 28,554,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively   29    29 
Additional paid-in capital   598,842    594,173 
Accumulated deficit   (566,212)   (518,314)
Accumulated other comprehensive loss   (953)   (869)
Total stockholders' equity   31,706    75,019 
Total liabilities and stockholders' equity  $84,728   $133,440 

 

 

ACUTUS MEDICAL, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

 

   Three Months Ended September 30,  Nine Months Ended September 30,
   2023  2022  2023  2022
   (unaudited)
Revenue  $5,238   $3,644   $14,696   $11,401 
Cost of products sold   8,595    6,951    23,447    23,589 
Gross profit   (3,357)   (3,307)   (8,751)   (12,188)
                     
Operating expenses (income):                    
Research and development   4,795    5,946    17,712    21,884 
Selling, general and administrative   7,432    9,679    26,280    38,207 
Goodwill impairment   —    —    —    12,026 
Restructuring   —    1,331    475    2,280 
Change in fair value of contingent consideration   —    198    123    1,153 
Gain on sale of business   (2,648)   —    (5,927)   (43,575)
Total operating expenses   9,579    17,154    38,663    31,975 
Loss from operations   (12,936)   (20,461)   (47,414)   (44,163)
                     
Other income (expense):                    
Loss on debt extinguishment   —    —    —    (7,947)
Change in fair value of warrant liability   636    904    1,478    904 
Interest income   547    241    2,223    292 
Interest expense   (1,409)   (1,109)   (4,110)   (3,810)
Total other income (expense), net   (226)   36    (409)   (10,561)
Loss before income taxes   (13,162)   (20,425)   (47,823)   (54,724)
Income tax expense   75    —    75    — 
Net loss  $(13,237)  $(20,425)  $(47,898)  $(54,724)
                     
Other comprehensive income (loss):                    
Unrealized gain on marketable securities   4    39    7    — 
Foreign currency translation adjustment   (66)   (351)   (91)   (904)
Comprehensive loss  $(13,299)  $(20,737)  $(47,982)  $(55,628)
                     
Net loss per common share, basic and diluted  $(0.45)  $(0.72)  $(1.65)  $(1.93)
Weighted average shares outstanding, basic and diluted   29,262,768    28,359,516    29,024,353    28,273,207 

 

 

ACUTUS MEDICAL, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

 

   Nine Months Ended
September 30,
   2023  2022
   (unaudited)
Cash flows from operating activities          
Net loss  $(47,898)  $(54,724)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   3,498    4,653 
AcQMap Systems converted to sales   238    266 
Sales-type lease gain   (310)   (87)
Amortization of intangible assets   150    370 
Non-cash stock-based compensation expense   4,915    7,497 
(Accretion of discounts) amortization of premiums on marketable securities, net   (1,318)   237 
Amortization of debt issuance cost   325    741 
Amortization of operating lease right-of-use assets   513    480 
Loss on debt extinguishment   —    7,947 
Goodwill impairment   —    12,026 
Gain on sale of business, net   (5,927)   (43,575)
Direct costs paid related to sale of business   —    (2,917)
Change in fair value of warrant liability   (1,478)   (904)
Loss on disposal of property and equipment   268    — 
Change in fair value of contingent consideration   123    1,153 
Changes in operating assets and liabilities:          
Accounts receivable   1,244    420 
Inventory   (2,401)   1,812 
Employer retention credit receivable   4,703    — 
Prepaid expenses and other current assets   420    (4,296)
Other assets   495    386 
Accounts payable   (2)   (2,929)
Accrued liabilities   (2,430)   (179)
Operating lease liabilities   (253)   (390)
Other long-term liabilities   20    (40)
Net cash used in operating activities   (45,105)   (72,053)
           
Cash flows from investing activities          
Proceeds from sale of business   17,000    50,000 
Purchases of available-for-sale marketable securities   (38,521)   (33,235)
Sales of available-for-sale marketable securities   —    18,599 
Maturities of available-for-sale marketable securities   70,250    59,642 
Purchases of property and equipment   (1,394)   (2,473)
Net cash provided by investing activities   47,335    92,533 
           
Cash flows from financing activities          
Repayment of debt   —    (44,550)
Penalty fees paid for early prepayment of debt   —    (1,063)
Borrowing under new debt   —    34,825 
Payment of debt issuance costs   —    (626)
Proceeds from the exercise of stock options   4    66 
Repurchase of common shares to pay employee withholding taxes   (275)   (62)
Proceeds from employee stock purchase plan   25    182 
Payment of contingent consideration   (1,923)   (873)
Net cash used in financing activities   (2,169)   (12,101)
           
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (294)   (447)
           
Net change in cash, cash equivalents and restricted cash   (233)   7,932 
Cash, cash equivalents and restricted cash, at the beginning of the period   31,348    24,221 
Cash, cash equivalents and restricted cash, at the end of the period  $31,115   $32,153 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $3,731   $3,101 

 

 

 

   Nine Months Ended
September 30,
   2023  2022
   (unaudited)
Supplemental disclosure of noncash investing and financing activities:      
Accounts receivable from sale of business  $6,111   $— 
Change in unrealized (gain) loss on marketable securities  $(7)  $— 
Change in unpaid purchases of property and equipment  $35   $48 
Contingent consideration escrow release  $—   $380 
Net book value on AcQMap system sales-type leases  $238   $244 
Amount of debt proceeds allocated to warrant liability  $—   $3,379 

 

 

ACUTUS MEDICAL, INC.

Reconciliation of GAAP Results to Non-GAAP Results

(in thousands)

(unaudited)

 

Three Months Ended September 30, 2023  Cost of Products Sold  Research and Development  Selling, General and Administrative  Loss from Operations  Other Expense, Net  Net Loss  Basic and Diluted EPS
Reported  $8,595   $4,795   $7,432   $(12,936)  $(226)  $(13,237)  $(0.45)
Amortization of acquired intangibles   (50)   —    —    50    —    50    — 
Stock-based compensation   (146)   (317)   (815)   1,278    —    1,278    0.04 
Change in fair value of warrant liability   —    —    —    —    (636)   (636)   (0.02)
Change in fair value of contingent consideration   —    —    —    —    —    —    0.00 
 Gain on sale of business   —    —    —    (2,648)   —    (2,648)   (0.09)
Adjusted  $8,399   $4,478   $6,617   $(14,256)  $(862)  $(15,193)  $(0.52)
                                    

 

Three Months Ended September 30, 2022  Cost of Products Sold  Research and Development  Selling, General and Administrative  Loss from Operations  Other Income (Expense), Net  Net Loss  Basic and Diluted EPS
Reported  $6,951   $5,946   $9,679   $(20,461)  $36   $(20,425)  $(0.72)
Amortization of acquired intangibles   (50)   —    —    50    —    50    — 
Stock-based compensation   (93)   (349)   (1,442)   1,884    —    1,884    0.07 
Change in fair value of warrant liability   —    —    —    —    (904)   (904)   (0.03)
Change in fair value of contingent consideration   —    —    —    198    —    198    0.01 
Restructuring   —    —    —    1,331    —    1,331    0.05 
Employee retention credit   813    414    919    (2,146)   —    (2,146)   (0.08)
Adjusted  $7,621   $6,011   $9,156   $(19,144)  $(868)  $(20,012)  $(0.70)
                                    

 

 

ACUTUS MEDICAL, INC.

Key Business Metrics

(unaudited)

Installed Base and Procedure Volumes

 

The total installed base which includes AcQMap Systems as of September 30, 2023 and 2022 are as follows:

 

   As of September 30,
   2023  2022
Acutus      
U.S.   26    32 
Outside the U.S.   56    42 
Total Acutus net system placements   82    74 

 

Procedure volumes for the three and nine months ended September 30, 2023 and 2022 are as follows:

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2023  2022  2023  2022
Procedure volumes   531    441    1,566    1,389 

 

Revenue

 

The following table sets forth the Company’s revenue for disposables, systems and service/other for the three and nine months ended September 30, 2023 and 2022 (in thousands):

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2023  2022  2023  2022
Disposables  $4,069   $2,857   $11,409   $9,402 
Systems   563    476    1,254    823 
Service / other   606    311    2,033    1,176 
Total revenue  $5,238   $3,644   $14,696   $11,401 

 

The following table presents revenue by geographic location for the three and nine months ended September 30, 2023 and 2022 (in thousands):

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2023  2022  2023  2022
United States  $3,347   $1,925   $8,720   $5,985 
Outside the United States   1,891    1,719    5,976    5,416 
Total revenue  $5,238   $3,644   $14,696   $11,401 

 

 

 EX-99.2 3 dp202619_ex9902.htm EXHIBIT 99.2

 

Exhibit 99.2

 

Press Release  

 

 

Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring

 

CARLSBAD, Calif., November 8, 2023 (GLOBE NEWSWIRE) – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring.

 

Scott Huennekens, Chairman of Acutus, commented, “Following an extensive strategic review by the Company’s Board of Directors, we are taking the hard but necessary steps to streamline our operations. In light of the current financing environment and the capital investments required to achieve leadership in the electrophysiology (EP) market, we have concluded that the optimal use of the Company’s resources is to reallocate capital from our mapping and ablation business to the manufacturing of left-heart access products for Medtronic, which we believe will maximize the potential for future earnouts and cash flow.”

 

David Roman, President & CEO of Acutus added, “The realignment of resources and corporate restructuring unfortunately impacts our team. It is undoubtedly difficult to part with our valued and highly talented colleagues who have made substantial contributions to our Company. I want to thank each one of them for their dedication to Acutus and our mission.”

 

Strategic Realignment of Resources and Corporate Restructuring
The Company is implementing a shift in its business model to solely support the manufacturing and distribution of Medtronic’s left-heart access products and to capture the value associated with potential earnout payments from Medtronic.

 

Under this new business model, the Company will wind down the EP mapping and ablation business, including the AcQMap Mapping System, the AcQMap 3D Mapping Catheter, the AcQBlate Force-Sensing Ablation Catheter, the AcGuide Max 2.0 steerable sheath, and associated accessories. The Company will support AcQMap procedures with a small group of therapy managers through November 30, 2023.

Acutus has begun implementation of a corporate restructuring to realign resources to support the left-heart access distribution business, which will result in reducing the Company’s workforce by approximately 65%. Restructuring actions are expected to meaningfully reduce cash burn as well as ongoing operating expenses and are expected to be completed in the first quarter of 2024.

 

Post restructuring, Acutus will become a contract manufacturing business with the potential to generate positive cash flow over the next several years. Further, the Company will continue to work with its strategic and financial advisors with the goal of maximizing the benefits of this new business model.

 

Financial Impact
Going forward, the Company’s exclusive sources of revenue will come from the sale of left-heart access products at transfer prices specified in Acutus’ existing distribution agreement with Medtronic and any fee-bearing transition services, with the Company’s operating expenses and working capital utilized to support manufacturing, quality, and supply chain related activities as well as general and administrative functions.

 

Under the Asset Purchase Agreement dated April 26, 2022, between Acutus and Medtronic, Acutus is eligible to receive net-sales earnouts under the following terms: 100% of total net end-user sales in year 1; 75% of total net end-user sales in year 2; and 50% of total net end-user sales in years 3 and 4. The annual measurement period for net sales earnouts began on January 30, 2023, and any such earnout payments would begin in April 2024 and continue annually each year thereafter until 2027.

 

As of September 30, 2023, the Company had $45.5 million in cash, cash equivalents, marketable securities, and restricted cash. Once restructuring actions are completed, the Company expects that cash

 

 

Press Release 

 

on hand, distribution revenue from left-heart access products to Medtronic, and future earn-outs will be sufficient to service the Company’s outstanding debt and fund the remaining business.

 

WARN Act
The WARN Act requires employers to provide sixty days advance notice to employees and certain government entities before conducting any mass layoff, relocation, or termination that affects more than fifty full-time employees and equivalents. The Company has notified affected employees and required government authorities.

 

About Acutus Medical 

Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

 

Caution Regarding Forward-Looking Statements 

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan on the expected timeline and within the expected cost range, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

Follow Acutus Medical on: X (Formerly Twitter), LinkedIn, and YouTube.

 

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

 

 

 GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 5 image_002.jpg GRAPHIC begin 644 image_002.jpg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image_003.jpg GRAPHIC begin 644 image_003.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^FLP49)P M/4TZN!\>W-QJE[IWA:QE*37;>;.RGE8Q_P#J_2@#O58,,CI2UQ'PXU>:?2I] M(O6/VW3I#$P;J5[?U'X5VP.10 C,%&20![TWSH_^>B?]]"O/?B9++)J&@:=Y MLB6UU<8E5&(W?\ @0U '8"5"8ZGX2 MET'Q1H,F@I?-&\W^DOYC, H*]3GCC-=WXD)'AG4R"01;2%@S.S?.W4Y_B-=V>E #!(K' ()[X/2E9U3&Y@,^IKSOX=.S>( M_%(9F(%WP">GS-TKJ/$7A2R\2M;F[EN(_(W;?)?;G..OY4 ;?G1_\]$_[Z%) MYT?]]/\ OH5X]XU\)67ATZ8+.>[;[3/Y;^9*3Q76+\+]$>,9GON1VG- 'U 'I%-#J6VY&[TS2GH:\[L'<_&B_4LQ46O SQT6@#T0\"F>='_?7_OH5SWC MZZGL_!>H36TK12A0 ZG!&2 ?I6#HWP\T?4-%LKR>6\,L\*R.1.>I&30!W_G1 M_P#/1/\ OH4\'(R*X.^^&.F"PG^Q2W7VKRSY.^<[=_;/M74>'+.]T_P_9VFH M3":ZB3:[@Y!_$]: -6BBB@"*>9+>!YI6"QHI9F)P !7GW@D_VMJ^K>+;P[(Y M7,-N6X"QC_(_6M;XCW%\OAA[33X)YI[MA$?)0L0O?..GI^-:FCZ#!:>%[729 M8@46)0X'=NI/YYJ97MIN-6OJ<'XOFG\)>,+3Q)88-I>@+< O>FKVU$_(S/B1_P C)X6_Z^?_ &9*]''05Y]\2M/U&2XT M;4K*TDNELYBSI$I8]5(X'7I53_A/_$7_ $+=Y_X#M3 ]$GOK6VGBAGN(HY9C M^[1V +_3U[54\2?\BSJ?_7M)_P"@FO-+BZUOQ;XJT.2;1KFW%G/N9Y(2JA<@ MG)/^[7I^N6\EWH5_;PKNED@=%&>I(H Y3X5#'A-?]]O_ $(UW?:O)O"6OW_A MG1A87'AW5))%8Y:. D=:WO\ A8-Q_P!"SK'_ (#F@"G\./\ D9?%7_7V?_0F MKT>O/?AO:7JWVNW]U9S6T=Y<;XUF3:W4D\'ZUZ%0!YS\5/OZ%_U]BO1(_P#5 MK]!7 _$NSNKM]%^S6TTVRZ!;RT+;1[XKO8_]6H[X% #STKS;PV/^+MZ^?^F? M_P 37I!Z5Y8\VH>&_B%JVHMHU]=P7*@1M;Q[@>GIM]TUYU8?\ ):]0 M_P"O3^BU;_X6#T.ZTUY3&)EP' ^Z0<7",K8@)#LN><8KFXO'FNQ0HG_".7[;5 R;=N: )M1TWQUIV MFW-Z_BB)E@B:0J+9)H\BV;C(Q77^ K"ZTWP=8VUY$8IE#$H>HRQ(H Z6BBB@!A< C M..>E&Y0<'&36;JUF]ZUJB[E"R%MZ_P )P<'\\56@M+W^V+>YN6W-L=6V_=4< M8_/K7/*K)2MRFJA%J]S>HHHKH,B(SQYP77/3K4ERM<6;R!I6/^J!X MSQS74#I6%&HYIW5C6I!1V=P[4QI44X+ 'W-//2L&[A']K32S6#7$;1H$(4'! MYSU_"G5J."NB814GJ;H8$9'(I:RM&M[B"&7S@41G+)&3]P9Z5K5<).4;L4E9 MV&D@ DXP.]&[VJIJ<;RZ;<)&"7:,@ =^*L0Y$2 CG XHYO>L*VER0TTR*O4@ M?4TX]*Q[N(C5UEDMVEA\K:,+G!SZ4JDW%:#C'F-82*WW2#]#3L5GV0C\^5H[ M1H <#<1C=^%:%.#YE<4E9V \"FAU)P",TV=S' [JIIT6!Z4?A0#D"E/2MC,9N7=MR,^E.K(O#+ M;ZS# EX-101.SCH 7 afib-20231106.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 afib-20231106_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 9 afib-20231106_pre.xml XBRL PRESENTATION FILE GRAPHIC 10 image_004.jpg GRAPHIC begin 644 image_004.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2023
Entity File Number 001-39430
Entity Registrant Name Acutus Medical, Inc.
Entity Central Index Key 0001522860
Entity Tax Identification Number 45-1306615
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2210 Faraday Ave.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code 442
Local Phone Number 232-6080
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol AFIB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 12 dp202619_8k_htm.xml IDEA: XBRL DOCUMENT 0001522860 2023-11-06 2023-11-06 iso4217:USD shares iso4217:USD shares false 0001522860 8-K 2023-11-06 Acutus Medical, Inc. DE 001-39430 45-1306615 2210 Faraday Ave. Suite 100 Carlsbad CA 92008 442 232-6080 false false false false Common Stock, par value $0.001 AFIB NASDAQ true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://acutusmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports afib-20231106.xsd afib-20231106_lab.xml afib-20231106_pre.xml dp202619_8k.htm image_001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dp202619_8k.htm": { "nsprefix": "AFIB", "nsuri": "http://acutusmedical.com/20231106", "dts": { "schema": { "local": [ "afib-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "afib-20231106_lab.xml" ] }, "presentationLink": { "local": [ "afib-20231106_pre.xml" ] }, "inline": { "local": [ "dp202619_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://acutusmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp202619_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp202619_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://acutusmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0000950103-23-016107-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-23-016107-xbrl.zip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end